Tinnitus, the persistent ringing in the ears affecting millions globally, has long challenged audiologists and frustrated patients alike. Traditional treatments—sound therapy, cognitive behavioral therapy, and amplification devices—often bring only temporary relief. But a groundbreaking new therapy, involving stimulating the tongue to retrain the brain, has emerged with surprising roots and compelling scientific backing.

This novel approach, known as bimodal neuromodulation, is the brainchild of Ross O'Neill, founder and CEO of Neuromod, the company behind Lenire, the first FDA-approved bimodal tinnitus treatment. The origins of Lenire trace back to an unexpected personal and professional convergence in O'Neill's life.